



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/644,579-Conf. #5200	
			Filing Date	August 20, 2003	
			First Named Inventor	Connie Sanchez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	05432/100M919-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
YC	AA**	US-2002/0103249-A1	08-01-2002	H. Lundbeck A/S	
YC	AB**	US-6,169,105-B1	01-2001	Wong et al.	
YC	AC**	US-6,184,219-B1	02-2001	Evenden et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
YC	1	Kasper, Siegfried, et al., "Escitalopram is Efficacious and well Tolerated in Treatment of Social Anxiety Disorder", ADAA National Conference, 21-24 March 2002, 1 page.			
YC	2	Stahl, Stephen, et al., "Escitalopram in the Treatment of Panic Disorder", Presented at the 22nd National Conference of the Anxiety Disorders Association of America, March 21-24, 2002, Austin, Texas, NR56, 1 page.			
YC	3	Huffman, Jeff C., et al., "The Development of New Antidepressants: Focus on Duloxetine and Escitalopram", Harv Rev Psychiatry, 11:30-36 (2003).			
YC	4	Burke, William J., "Escitalopram", Expert Opin. Investig. Drugs, 11(10): 1477-1486 (2002).			
YC	5	Farah, Andrew, "Therapeutic Advantages of Escitalopram in Depression and Anxiety Disorders", Primary Psychiatry, 9(12): 30-35 (2002).			
YC	6	Waugh, John, et al., "Escitalopram, A review of its Use in the Management of Major Depressive and Anxiety Disorders", CNS Drugs, 17 (5): 343-362 (2003).			
YC	7	Lader, Malcolm, et al., "Efficacy and Tolerability of Escitalopram in 12- and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study", Depression and Anxiety, 19: 241-248 (2004).			
YC	8	Davidson, Jonathan, et al., "Escitalopram in the Treatment of Generalized Anxiety Disorder", Presented at the 22nd National Conference of the Anxiety Disorder Association of America, March 21-24, 2002, Austin, Texas, NR57, 1 page.			
YC	9	Poster, "Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, 9-12 April 2003, Juan-les-Pins, France, 1 page.			
YC	10	Stahl, et al., J. Clin. Psychiatry 2003; 64: 1322-1327.			
YC	11	Montgomery, S.A., et al., "The antidepressant efficacy of citalopram", International Clinical Psychopharmacology (1996), Vol. 11, Supplement 1, pp. 29-33.			

Examiner Signature	<i>Yong Chong</i>	Date Considered	6/14/05
-----------------------	-------------------	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/644,579-Conf. #5200	
			Filing Date	August 20, 2003	
			First Named Inventor	Connie Sanchez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	05432/100M919-US1

YC	12	Bouchard, J.M., et al., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial", Journal of Affective Disorders, Vol. 46, pp. 51-58 (1997).	
----	----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Yong Chong</i>	Date Considered	6/14/05
-----------------------	-------------------	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/644,579	
			Filing Date	August 20, 2003	
			First Named Inventor	Connie Sanchez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	05432/100M919-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
Yc	1.	US-6,469,064 B2	10-22-2002	Druzgala	
Yc	2.	US-6,333,357 B1	12-25-2001	Eig	
Yc	3.	US-6,159,971	12-12-2000	Berg et al.	
Yc	4.	US-6,147,072	11-14-2000	Bymaster et al.	
Yc	5.	US-6,069,177	05-30-2000	Carlier et al.	
Yc	6.	US-5,962,514	10-05-1999	Evenden et al.	
Yc	7.	US-5,958,429	09-28-1999	Wong	
Yc	8.	US-5,788,986	08-04-1998	Dodman	
Yc	9.	US-5,648,396	07-15-1997	Young et al.	
Yc	10.	US-5,296,507	03-22-1994	Tanaka et al.	
Yc	11.	US-5,114,976	05-19-1992	Norden	
Yc	12.	US-4,962,128	10-09-1990	Doogen et al.	
Yc	13.	US-4,943,590	07-24-1990	Boegesoe et al.	
Yc	14.	US-4,902,710	02-20-1990	Foster et al.	
Yc	15.	US-4,650,884	01-23-1979	Bogeso et al.	
Yc	16.	US-4,136,193	01-23-1979	Bogeso et al.	
Yc	17.	US-3,467,675	09-16-1969	Peterson et al.	
Yc	18.	US-Re. 34712	08-30-1994	Boegesoe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
Yc	19.	EP-0 347 066 A1	12-20-1989	H. Lundbeck A/S		
Yc	20.	WO-01/03694 A1	01-18-2001	H. Lundbeck A/S		
Yc	21.	WO-00/15220	03-23-2000	Astra Aktiebolag		
Yc	22.	WO-01/54681 A2	08-02-2001	Massachusetts Institute of Technology		
Yc	23.	WO-00/15219	03-23-2000	Astra Aktiebolag		
Yc	24.	WO-00/03701	01-27-2000	Massachusetts Institute of Technology		
Yc	25.	WO-00/02551	01-20-2000	NPS Pharmaceutical, Inc.		
Yc	26.	EP-0759299	02-26-1997	Eli Lilly and Company		
Yc	27.	EP-0714663 A2	06-05-1996	Eli Lilly and Company		
Yc	28.	WO-93/09769	05-27-1993	Sepracor, Inc.		
Yc	29.	WO-92/18005	10-29-1992	National Institutes of Health		
Yc	30.	WO-00/34263	06-15-2000	H. Lundbeck A/S		
Yc	31.	EP-0474580	03-11-1992	H. Lundbeck A/S		

(W:1054 321100)	<i>[Signature]</i>	Date Considered	6/14/05
--------------------	--------------------	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitutes for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/644,579	
			Filing Date	August 20, 2003	
			First Named Inventor	Connie Sanchez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	05432/100M919-US1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
Yc	32.	Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 18-25		
Yc	33.	Nierenberg, A.A and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9		
Yc	34.	Sackeim, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17		
Yc	35.	Willner, P., Psychopharmacology, 1997, 134, 319-329		
Yc	36.	A.F. Joubert et al., "Citalopram and Anxiety Disorders," Rev. Contemp. Pharmacother 10: 79-131 (1999)		
Yc	37.	Ulla M. Lepola et al., "A Controlled Perspective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder," J. Clin. Psychiatry 59, 10: 528-534 (1998)		
Yc	38.	H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," Acta Psychiatrica Scandinavica 96:343-346 (1997)		
Yc	39.	Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," Journal of Serotonin Research 1: 29-33 (1996)		
Yc	40.	Bigler, Allan et al., "Quantitative Structure-activity Relationships in a Series of Selective 5-HT uptake inhibitors," Eur. J. Med. Chem. 3:289-295 (1997)		
Yc	41.	Soraya Seedat et al., "Open Trial of Citalopram in adults with post-traumatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000)		
Yc	42.	Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383:223-229 (1999)		
Yc	43.	Jennifer Y. Tan et al., "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999)		
Yc	44.	Mario Amore et al., "Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Fluoxetine vs. Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999)		
Yc	45.	Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997)		
Yc	46.	Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7:241-242 (1997)		
Yc	47.	Takeshi Inoue et al., "Effect of italoqram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996)		

(W:1054 321100)	<i>Zhong Chang</i>	Date Considered	6/14/05
--------------------	--------------------	-----------------	---------



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/644,579	
			Filing Date	August 20, 2003	
			First Named Inventor	Connie Sanchez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	05432/100M919-US1

Yc	48.	U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996)	
Yc	49.	J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995)	
Yc	50.	American Psychiatric Associations, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994)	
Yc	51.	Hyttel, J., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 1982, 6, 277-295	
Yc	52.	Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486	
Yc	53.	Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats, Behav. Pharmacol. 1993; 4:267-277	
Yc	54.	Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995)	
Yc	55.	Sanchez, C., R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model, European Journal of Pharmacology, 464, 2003, pp.155-158	
Yc	56.	Montgomery, S. et al., Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model, Pharmacology & Toxicology, 2001, 88, 282-286	
Yc	57.	Sanchez, C., Stress-induced vocalisation in adult animals: A valid model of anxiety?, European Journal of Pharmacology, 463 (2003) 133-143	
Yc	58.	Burke, W., et al., Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients, J. Clin Psychiatry, 63:4, April 2002	
Yc	59.	Wade, A., et al., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care, International Clinical Psychopharmacology 2002, Vol. 17 No. 3	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

(W:1054 321100)	<i>Yong Chong</i>	Date Considered	6/14/05
--------------------	-------------------	--------------------	---------